ALPHARETTA, Ga.--(BUSINESS WIRE)--Dune Medical Devices, (Alpharetta, GA), a medical device company focused on improving the effectiveness and outcome of cancer therapy through real-time tissue characterization, is presenting cutting-edge data and an expanded technology platform during the 2019 San Antonio Breast Cancer Symposium (SABCS) December 10-14.
Dune Medical is known primarily for its MarginProbe device for intraoperative margin assessment, shown to reduce re-excisions in breast conserving surgery by over 50%, and has been used in over 20,000 procedures.
The abstract, entitled "Feasibility of incorporating miniaturized, flexible radiofrequency (RF) sensors in a breast biopsy needle for accurate real-time characterization of benign and malignant tissue," reports on data collected at three medical facilities in Israel and will be presented by Avihai Lachman, Vice President Research & Development, Dune Medical.
It has been well established that physiologic differences between benign and malignant tissues are reflected in their electrical properties. “Access to real-time tissue properties during the biopsy procedure has the potential for increasing accuracy by enabling the most suspicious tissue to be sampled, and by providing the tissue characterization to pathology for comparison with histologic findings,'' said Dr. Tanir Allweis, Director, Breast Health Center, Kaplan Medical Center, Rehovot, Israel.
The results of this feasibility study demonstrate that breast tissue can be characterized in real-time during the biopsy procedure, providing constant information on the makeup of the tissue with which the needle is in contact. With a sensitivity of 85% and a specificity of 99%, this data affirms that radiofrequency spectroscopy is applicable in a multitude of applications, leading not only to more accurate tissue sampling and diagnosis, but expanded opportunities for delivering targeted therapies in the future.
“The ability to accurately characterize tissue properties in real-time during the biopsy procedure is a game changer. Studies show that there is a 25% discordance rate for breast biopsy diagnostic interpretation, which can affect how a patient is managed. Providing physicians with the ability to sample the most suspicious tissue will ensure that the most relevant biopsy cores are retrieved, enabling the most accurate diagnosis,“ states Lori Chmura, Dune Medical CEO.
The development of the Smart Biopsy device was made possible through the coveted European Union Horizon 2020 research grant awarded in 2016, and the technology is currently being tested in vivo. In presenting this compelling data at SABCS, Dune Medical reaches a major milestone, marking significant achievement toward its mission to make RF spectroscopy technology available across the oncology spectrum.
The San Antonio Breast Cancer Symposium, a collaboration of the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO), has brought the international oncology community together to share and collaborate about the latest advancements and research in breast cancer since 1977. Dune Medical will be presenting December 13, from 5-7 pm, during Poster Session 5, Ongoing Trials, Program #OT3-04-01.
About Dune Medical Devices
Imagine not having to wonder, “Did we get it all?”
At Dune Medical Devices, we believe in reducing the anxiety that waiting for pathology results places on a patient and their families. Our solutions, which are developed on a first-of-its-kind RF Spectroscopy platform, can differentiate cancerous from healthy tissue based on electromagnetic properties, making it possible for patients and physicians to answer the question, “Did we get it all?” For more information, contact email@example.com.